MIST stock jumps as late-stage trial for lead drug meets main goal (NASDAQ:MIST)
seekingalpha.com
finance
2022-10-17 11:18:07

Tatiana Syrtseva/iStock via Getty Images Milestone Pharmaceuticals (NASDAQ:MIST), a company focused on cardiovascular medicines, announced Monday that its lead asset, etripamil reached the primary endpoint in a Phase 3 trial for patients with the heart condition paroxysmal supraventricular tachycardia (PSVT). MIST shares added ~31% pre-market in reaction. About 2M Americans suffer from PSVT, a cardiovascular condition characterized by brief periods of rapid heartbeat. Disclosing the topline data, MIST said that the 706-patient global trial named RAPID met the primary endpoint as ~64% of patients who self-administered the calcium channel blocker converted to sinus rhythm within 30 minutes with statistical significance compared to ~31% on placebo.
